323 related articles for article (PubMed ID: 16566617)
1. Treatment adherence among patients with bipolar or manic disorder taking atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
J Clin Psychiatry; 2006 Feb; 67(2):222-32. PubMed ID: 16566617
[TBL] [Abstract][Full Text] [Related]
2. Treatment adherence among patients with schizophrenia treated with atypical and typical antipsychotics.
Gianfrancesco FD; Rajagopalan K; Sajatovic M; Wang RH
Psychiatry Res; 2006 Nov; 144(2-3):177-89. PubMed ID: 17010448
[TBL] [Abstract][Full Text] [Related]
3. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
4. Hospitalization risks in the treatment of bipolar disorder: comparison of antipsychotic medications.
Gianfrancesco F; Rajagopalan K; Goldberg JF; Wang RH
Bipolar Disord; 2007 May; 9(3):252-61. PubMed ID: 17430300
[TBL] [Abstract][Full Text] [Related]
5. Comparing adherence to and persistence with antipsychotic therapy among patients with bipolar disorder.
Hassan M; Madhavan SS; Kalsekar ID; Makela EH; Rajagopalan K; Islam S; Kavookjian J; Miller LA
Ann Pharmacother; 2007 Nov; 41(11):1812-8. PubMed ID: 17925501
[TBL] [Abstract][Full Text] [Related]
6. Medication patterns and costs associated with olanzapine and other atypical antipsychotics in the treatment of bipolar disorder.
Zhu B; Kulkarni PM; Stensland MD; Ascher-Svanum H
Curr Med Res Opin; 2007 Nov; 23(11):2805-14. PubMed ID: 17910804
[TBL] [Abstract][Full Text] [Related]
7. Comparison of mental health resources used by patients with bipolar disorder treated with risperidone, olanzapine, or quetiapine.
Gianfrancesco F; Pesa J; Wang RH
J Manag Care Pharm; 2005 Apr; 11(3):220-30. PubMed ID: 15804206
[TBL] [Abstract][Full Text] [Related]
8. Real-world adherence assessment of lurasidone and other oral atypical antipsychotics among patients with schizophrenia: an administrative claims analysis.
Rajagopalan K; Wade S; Meyer N; Loebel A
Curr Med Res Opin; 2017 May; 33(5):813-820. PubMed ID: 28098496
[TBL] [Abstract][Full Text] [Related]
9. The association between treatment adherence and antipsychotic dose among individuals with bipolar disorder.
Gianfrancesco FD; Sajatovic M; Rajagopalan K; Wang RH
Int Clin Psychopharmacol; 2008 Nov; 23(6):305-16. PubMed ID: 18854718
[TBL] [Abstract][Full Text] [Related]
10. Quetiapine versus other atypical antipsychotics for schizophrenia.
Asmal L; Flegar SJ; Wang J; Rummel-Kluge C; Komossa K; Leucht S
Cochrane Database Syst Rev; 2013 Nov; (11):CD006625. PubMed ID: 24249315
[TBL] [Abstract][Full Text] [Related]
11. Diagnoses associated with use of atypical antipsychotics in a commercial health plan: a claims database analysis.
Citrome L; Kalsekar I; Guo Z; Laubmeier K; Hebden T
Clin Ther; 2013 Dec; 35(12):1867-75. PubMed ID: 24119767
[TBL] [Abstract][Full Text] [Related]
12. Patterns of discontinuation of atypical antipsychotics in the province of Québec: A retrospective prescription claims database analysis.
Moisan J; Grégoire JP
Clin Ther; 2010; 32 Suppl 1():S21-31. PubMed ID: 20152549
[TBL] [Abstract][Full Text] [Related]
13. Atypical antipsychotics in the treatment of affective symptoms: a review.
Masan PS
Ann Clin Psychiatry; 2004; 16(1):3-13. PubMed ID: 15147108
[TBL] [Abstract][Full Text] [Related]
14. Atypical antipsychotics: newer options for mania and maintenance therapy.
Vieta E; Goikolea JM
Bipolar Disord; 2005; 7 Suppl 4():21-33. PubMed ID: 15948764
[TBL] [Abstract][Full Text] [Related]
15. One-year risk of psychiatric hospitalization and associated treatment costs in bipolar disorder treated with atypical antipsychotics: a retrospective claims database analysis.
Kim E; You M; Pikalov A; Van-Tran Q; Jing Y
BMC Psychiatry; 2011 Jan; 11():6. PubMed ID: 21214937
[TBL] [Abstract][Full Text] [Related]
16. Association between antipsychotic combination therapy and treatment adherence among individuals with bipolar disorder.
Gianfrancesco FD; Sajatovic M; Tafesse E; Wang RH
Ann Clin Psychiatry; 2009; 21(1):3-16. PubMed ID: 19239828
[TBL] [Abstract][Full Text] [Related]
17. Cost analysis of the treatment of schizophrenia in Thailand: a simulation model comparing olanzapine, risperidone, quetiapine, ziprasidone and haloperidol.
Kongsakon R; Leelahanaj T; Price N; Birinyi-Strachan L; Davey P
J Med Assoc Thai; 2005 Sep; 88(9):1267-77. PubMed ID: 16536115
[TBL] [Abstract][Full Text] [Related]
18. Typical and atypical antipsychotics in bipolar depression.
Gao K; Gajwani P; Elhaj O; Calabrese JR
J Clin Psychiatry; 2005 Nov; 66(11):1376-85. PubMed ID: 16420074
[TBL] [Abstract][Full Text] [Related]
19. Time to discontinuation of atypical versus typical antipsychotics in the naturalistic treatment of schizophrenia.
Ascher-Svanum H; Zhu B; Faries D; Landbloom R; Swartz M; Swanson J
BMC Psychiatry; 2006 Feb; 6():8. PubMed ID: 16504026
[TBL] [Abstract][Full Text] [Related]
20. Treatment of bipolar disorder: the evolving role of atypical antipsychotics.
Perlis RH
Am J Manag Care; 2007 Nov; 13(7 Suppl):S178-88. PubMed ID: 18041879
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
